Arrowhead Pharmaceuticals, Inc.
ARWR
$21.33
$0.582.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -148.42M | -143.97M | -639.71M | -599.49M | -538.64M |
| Total Depreciation and Amortization | 22.57M | 21.13M | 19.57M | 18.60M | 17.43M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 119.62M | 113.31M | 100.34M | 92.96M | 93.73M |
| Change in Net Operating Assets | 28.08M | 70.68M | 28.52M | 25.09M | 75.91M |
| Cash from Operations | 21.85M | 61.15M | -491.28M | -462.85M | -351.56M |
| Capital Expenditure | -39.47M | -51.55M | -80.33M | -141.47M | -181.09M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -385.37M | -507.73M | -327.67M | -278.60M | 14.45M |
| Cash from Investing | -424.84M | -559.28M | -408.00M | -420.07M | -166.64M |
| Total Debt Issued | 399.10M | 392.00M | 392.00M | 392.00M | -- |
| Total Debt Repaid | -201.63M | -151.63M | -- | -- | -- |
| Issuance of Common Stock | 245.09M | 245.25M | 432.02M | 431.65M | 432.25M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 16.87M | 66.87M | 66.87M | 46.87M | 50.00M |
| Cash from Financing | 459.43M | 552.49M | 890.89M | 870.52M | 482.25M |
| Foreign Exchange rate Adjustments | 3.96M | 3.64M | 4.07M | 4.20M | 14.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 60.39M | 58.01M | -4.33M | -8.21M | -35.94M |